4,248 Eli Lilly and Company $LLY Shares Sold by Cercano Management LLC

Cercano Management LLC decreased its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 79.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,105 shares of the company’s stock after selling 4,248 shares during the quarter. Cercano Management LLC’s holdings in Eli Lilly and Company were worth $1,279,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of LLY. Warner Group LLC increased its position in shares of Eli Lilly and Company by 9.9% during the third quarter. Warner Group LLC now owns 4,246 shares of the company’s stock worth $4,913,000 after purchasing an additional 383 shares in the last quarter. Tilson Financial Group Inc. acquired a new position in Eli Lilly and Company in the 3rd quarter valued at $248,000. Proactive Wealth Strategies LLC raised its stake in Eli Lilly and Company by 1.3% in the 3rd quarter. Proactive Wealth Strategies LLC now owns 9,798 shares of the company’s stock valued at $11,351,000 after purchasing an additional 129 shares during the last quarter. BCS Private Wealth Management Inc. lifted its holdings in Eli Lilly and Company by 29.3% in the 3rd quarter. BCS Private Wealth Management Inc. now owns 2,209 shares of the company’s stock valued at $2,556,000 after purchasing an additional 500 shares in the last quarter. Finally, Hall Capital Management Co. Inc. lifted its holdings in Eli Lilly and Company by 8.6% in the 3rd quarter. Hall Capital Management Co. Inc. now owns 2,811 shares of the company’s stock valued at $3,253,000 after purchasing an additional 223 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president owned 4,137 shares in the company, valued at $5,802,225.24. The trade was a 54.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent research reports. Wells Fargo & Company lifted their target price on shares of Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Truist Financial reaffirmed a “buy” rating and set a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a report on Friday, October 30th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Royal Bank Of Canada raised their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock an “outperform” rating in a research note on Friday, October 30th. Finally, Berenberg Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price target on the stock in a research report on Tuesday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,422.00.

View Our Latest Research Report on LLY

Trending Headlines about Eli Lilly and Company

These are some of the LLY headlines that stood out recently:

  • Positive Sentiment: Lilly agreed to acquire Calytrix Bio for up to $1.5 billion, adding experimental treatments for rare blood cancers—essential thrombocythemia and myelofibrosis—and broadening its portfolio beyond obesity drugs. The medicines are still in development, so their commercial potential is not yet established. Read article
  • Positive Sentiment: Retatrutide beat Novo Nordisk’s Ozempic in a head-to-head trial, a result that could reinforce Lilly’s competitive position in the expanding GLP-1 market. One report estimates that market could reach $190 billion by 2035. Read article
  • Positive Sentiment: New ObesityWeek data covered Zepbound, Foundayo, EloraTZP, and retatrutide, with reported efficacy signals across weight loss and related conditions. The findings may support Lilly’s pipeline and future growth prospects. Read article

Eli Lilly and Company Price Performance

NYSE:LLY opened at $1,431.12 on Tuesday. Eli Lilly and Company has a one year low of $850.51 and a one year high of $1,475.25. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The stock has a market cap of $1.35 trillion, a PE ratio of 46.45, a P/E/G ratio of 1.71 and a beta of 0.40. The stock has a 50 day moving average price of $1,247.93 and a 200 day moving average price of $1,112.33.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion for the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The firm’s revenue was up 38.6% compared to the same quarter last year. During the same quarter last year, the business posted $7.02 earnings per share. Equities research analysts expect that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is 22.46%.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.